Compare TKNO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | OVID |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 421.8M |
| IPO Year | 2021 | 2017 |
| Metric | TKNO | OVID |
|---|---|---|
| Price | $7.01 | $2.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $9.67 | $6.00 |
| AVG Volume (30 Days) | 564.9K | ★ 1.6M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,520,000.00 | $7,252,000.00 |
| Revenue This Year | $13.54 | N/A |
| Revenue Next Year | $14.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.35 | ★ 1181.27 |
| 52 Week Low | $1.91 | $1.18 |
| 52 Week High | $9.48 | $3.11 |
| Indicator | TKNO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 44.02 |
| Support Level | $6.33 | $2.09 |
| Resistance Level | $7.66 | $2.87 |
| Average True Range (ATR) | 0.59 | 0.17 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 53.90 | 27.68 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.